JSMC
RNTX

Jess S. Morgan & Co’s Rein Therapeutics RNTX Stock Holding History

Jess S. Morgan & Co’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,000
Closed -$51K – 47
2022
Q1 		$51K Hold
5,000
– – 0.04% 42
2021
Q4 		$56K Buy
5,000
+1,250
+33% +$19.3K 0.03% 44
2021
Q3 		$76K Hold
3,750
– – 0.05% 40
2021
Q2 		$94K Buy
3,750
+500
+15% +$12.5K 0.06% 40
2021
Q1 		$93K Hold
3,250
– – 0.07% 44
2020
Q4 		$68K Sell
3,250
-250
-7% -$6.25K 0.05% 40
2020
Q3 		$90K Hold
3,500
– – 0.09% 39
2020
Q2 		$83K Sell
3,500
-1,500
-30% -$24.4K 0.09% 38
2020
Q1 		$33K Sell
5,000
-1,250
-20% -$15.1K 0.04% 38
2019
Q4 		$72K Buy
+6,250
New +$61.7K 0.07% 40

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Jess S. Morgan & Co's RNTX Position: Q2 2022 in Review

Jess S. Morgan & Co sold out of Rein Therapeutics (RNTX) in Q2 2022, closing a stake of 5,000 shares — an estimated $51K sold.

Jess S. Morgan & Co first reported a position in RNTX in Q4 2019 and held it in 10 quarters. The position peaked at $94K in Q2 2021. 37 funds tracked by Wall St. Rank hold RNTX as of Q2 2022.

  • Jess S. Morgan & Co reported no remaining Rein Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Jess S. Morgan & Co sold 5,000 Rein Therapeutics shares in Q2 2022, an estimated $51K.
  • Jess S. Morgan & Co first reported a position in Rein Therapeutics in Q4 2019 and held it in 10 quarters.
  • Jess S. Morgan & Co's Rein Therapeutics position peaked at $94K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2022.

Based on Jess S. Morgan & Co's 13F filing for Q2 2022, filed 18 Jul 2022.